Bregua Corp 3
3 · Janux Therapeutics, Inc. · Filed Jun 10, 2021
Insider Transaction Report
Form 3
Bregua Corp
10% Owner
Holdings
Series B Convertible Preferred Stock
→ Common Stock (247,123 underlying)Series A Convertible Preferred Stock
→ Common Stock (674,211 underlying)Series Seed 2 Convertible Preferred Stock
→ Common Stock (1,630,428 underlying)Series Seed Convertible Preferred Stock
→ Common Stock (1,138,665 underlying)
Footnotes (2)
- [F1]Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- [F2]These securities are held directly by Bregua Corporation (Bregua). Klaus Dorner is the Director of Bregua and may be deemed to have voting and investment power with respect to the shares held by Bregua and as a result may be deemed to have beneficial ownership of such shares. Mr. Dorner disclaims beneficial ownership of all shares held by Bregua, except to the extent of his actual pecuniary interest therein, if any.